TA274 Macular oedema (diabetic) - ranibizumab: costing template
Revised template published June 2013
A costing template has been produced that can be used by health communities to assess the local impact of implementing the guidance, based on the local population. The national assumptions used in the template can be altered to reflect local circumstances.
The template has been prepared in consultation with the manufacturer and experts working in this area and has been approved for publication by NICE.
Disclaimer
This resource is an implementation tool and should be used alongside the published guidance. The information does not supersede or replace the guidance itself.
The Institute would welcome feedback from users to inform the development of future templates. Please email your comments to costing@nice.org.uk
|
TA274 Macular oedema (diabetic) - ranibizumab: costing template
27 February 2013 (589.5 Kb 2 mins 51 sec) |
This page was last updated: 06 June 2013